The AAT-AD/PD™ Focus Meeting 2020:Late-breaking abstract submissions closing soon

External Event - 2nd to 5th Apr 2020

We invite you to join us for the 2nd AAT-AD/PD™ Focus Meeting 2020 in Vienna, Austria. The first AAT-AD/PD™  Focus Meeting 2018 was held in Torino, Italy with 1337 participants.

The Meeting will present all the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer’s, Parkinson’s and other related neurological disorders.

A central theme will be to further advance innovative strategies in therapy and prevention, clinical trials and diagnostic markers discussed in the sessions and corridors at AD/PD™ 2019, in order to focus on driving successful collaborations among academia and industry, leading to the development of innovative therapies and ultimately providing for a better future for patients and families affected by neurodegenerative diseases.

Join us 2-5 April 2020 in the beautiful city of Vienna, Austria.

Please note there is an increasing number of fake websites and agencies claiming to offer hotel and registration services for AAT-AD/PD™ 2020. We would like to alert all conference participants to be aware of possible scams and only use the trusted online accommodation and online registration services for bookings. If you are contacted by a third party offering accommodation or registration this is likely to be fraudulent activity. Please click here to contact us here if you require further assistance.

For more information and to submit your abstract, please click here. 

THE 2020 PARTIAL LIST OF CONFIRMED PLENARY SPEAKERS ARE:

Jesse Cedarbaum, USA

Coeruleus Clinical Sciences | 16 Old Barnabas Rd, Woodbridge, CT 06525, USA

DIGITAL TECHNOLOGIES, BRIGHT SHINY OBJECTS AND THE FUTURE OF CLINICAL TRIALS IN PARKINSON’S DISEASE

Jeff Cummings, USA

University of Nevada Las Vegas (UNLV) School of Allied Health Sciences and Cleveland Clinic Lou Ruvo Center for Brain Health

ALZHEIMER’S DRUG DEVELOPMENT PIPELINE:  NOVEL TARGETS AND INNOVATIVE APPROACHES

Miia Kivipelto, Sweden

Senior Geriatrician, Director of Research, Development, Education and Innovation Karolinska University Hospital |Theme Aging, Karolinska Institute | Dept NVS | Division of Clinical Geriatrics | Center for Alzheimer Research

WORLD-WIDE FINGERS AND THE NEXT GENERATION OF CLINICAL TRIALS IN ALZHEIMER´S DISEASE

Julie Schneider, USA

The Deborah R. And Edgar D. Jannotta Presidential Professor of Pathology and Neurological Sciences Associate Director, Rush Alzheimer’s Disease Center, Rush University Medical Center

THE CONTRIBUTION OF TDP43 TO COGNITIVE DISORDERS OF LATE LIFE